FDA approves Roche’s “tumour agnostic” drug RozlytrekThe FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in Share XFDA approves Roche’s “tumour agnostic” drug Rozlytrekhttps://pharmaphorum.com/news/fda-approves-roches-tumour-agnostic-drug-rozlytrek/
AbbVie/Janssen win EU approval for two new Imbruvica usesEuropean regulators have approved AbbVie and Janssen’s Imbruvica (ibrutinib) in two expanded uses that broaden the use of Share XAbbVie/Janssen win EU approval for two new Imbruvica useshttps://pharmaphorum.com/news/eu-regulators-approve-two-new-uses-for-janssens-imbruvica/
Boehringer jumps on KRAS cancer drug bandwagon with MD AndersonBoehringer Ingelheim has become the latest pharma company to investigate KRAS as a potential target for cancer drugs, Share XBoehringer jumps on KRAS cancer drug bandwagon with MD Andersonhttps://pharmaphorum.com/news/boehringer-jumps-on-kras-cancer-drug-bandwagon-with-md-anderson/
AZ’s lung cancer drug Tagrisso gets boost from first line OS resultsAstraZeneca has announced figures confirming that its Tagrisso extends overall survival in patients with untreated non-small cell lung Share XAZ’s lung cancer drug Tagrisso gets boost from first line OS resultshttps://pharmaphorum.com/news/azs-key-cancer-drug-tagrisso-gets-further-boost-from-os-results/
Could Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?Kyowa Kirin has bought back rights outside of cancer to tivozanib, amending an agreement dating back to 2006 Share XCould Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?https://pharmaphorum.com/news/could-kyowa-kirin-be-eyeing-ophthalmology-use-for-cancer-drug-tivozanib/
NEC buys OncoImmunity to boost AI-based cancer researchJapanese multinational NEC has bought the Norway-based bioinformatics firm OncoImmunity, which develops proprietary machine learning software to support Share XNEC buys OncoImmunity to boost AI-based cancer researchhttps://pharmaphorum.com/news/nec-buys-oncoimmunity-to-boost-ai-based-cancer-research/
BMS shares fall on mixed cancer immunotherapy resultsBristol-Myers Squibb’s shares have fallen sharply in pre-opening trading after mixed results from its cancer immunotherapy Opdivo in Share XBMS shares fall on mixed cancer immunotherapy resultshttps://pharmaphorum.com/news/bms-shares-fall-on-mixed-cancer-immunotherapy-results/
More woe for Roche as another Rituxan biosimilar approved in USThe FDA has approved a second biosimilar of Roche’s leukaemia drug Rituxan, along with yet another biosimilar of Share XMore woe for Roche as another Rituxan biosimilar approved in UShttps://pharmaphorum.com/news/more-woe-for-roche-as-another-rituxan-biosimilar-approved-in-us/
Did cancer clinical trials stay on track at ASCO 2019?Chicago is recovering after 40,000 oncologists and cancer experts descended on the city for this year’s ASCO conference. Share XDid cancer clinical trials stay on track at ASCO 2019?https://deep-dive.pharmaphorum.com/magazine/oncology-asco-2019/kantar-cancer-clinical-trials/
